HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Wednesday, 16 March 2011

Recent cost-utility analyses

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 24 papers were listed this time. Here's a handful:

Lynch FL, Dickerson JF, Clarke G, et al. Incremental Cost-effectiveness of Combined Therapy vs Medication Only for Youth With Selective Serotonin Reuptake Inhibitor-Resistant Depression: Treatment of SSRI-Resistant Depression in Adolescents Trial Findings. Arch Gen Psychiatry. 2011 Mar;68(3):253-62. PubMed PMID: 21383263.

Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011 Mar 2. [Epub ahead of print] PubMed PMID: 21371999.

Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin  Pharmacol Ther. 2011 Mar;49(3):217-30. PubMed PMID: 21329624.

Grosso AM, Bodalia PN, Macallister RJ, et al. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011 Mar;65(3):253-63. Epub 2011 Feb 1. PubMed PMID: 21284790.

Borgström F, Ström O, Kleman M, et al. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int. 2011 Mar;22(3):955-65. Epub 2010 Jun 8. PubMed PMID: 20532482.